Clinical efficacy of magnesium orotate in the therapy of cardiovascular diseases
Shehyan G.G.^1, Yalymov A.A.^1, Schikota A.M.^1,. Zadionchenko V.S.^1, Terpigorev S.A.^2, Kabanova T.G.^2, Shirokova E.B.<sup>2

1</sup> Moscow State Medical Stomatological University named after A.I.Evdokimov
² M.F. Vladimirskiy Moscow Regional Research and Clinical Institute

The article describes the oral preparation of magnesium - magnesium orotate. Magnesium regulates the metabolic processes in the body, participating in the plastic, energy and electrolyte metabolism. The magnesium deficiency in the population is found in 16-42%, which can be clinically manifested in cardiovascular disorders. The article gives the definition of hypomagnesemia and describes its reasons (not only the low magnesium content in foods and drinking water, but also the slow gastrointestinal motility in the elderly, dysbacteriosis, malabsorption syndrome, alcohol abuse, pregnancy, lactation, stress, chronic fatigue syndrome, etc.). The article describes in detail the effects of magnesium ions and orotic acid, which are included into the drug Magnnerot®. The article presents the results of multicenter randomized studies of magnesium orotate in patients with cardiovascular diseases (mitral valve prolapse, arterial hypertension, myocardial infarction and heart failure, heart rhythm disturbances). The results of studies suggest that administration of magnesium orotate in addition to the basic therapy contributes to an increase in the efficiency of the treatment and improves the quality of life of the patients. Thus, the drug Magnneroth® can be recommended to the patients with cardiac diseases.

Key words: magnesium orotate, potassium, magnesium, hypomagnesemia, connective tissue dysplasia, mitral valve prolapse, arterial hypertension, heart failure, prolonged QT interval, myocardial
For citation: Shehyan G.G., Yalymov A.A., Schikota A.M. et al. Clinical efficacy of magnesium orotate in the therapy of cardiovascular diseases // RMJ. 2017. № 4. P. 273–278.